[Comment] Natalizumab in secondary progressive multiple sclerosis

Although several disease-modifying treatments are available for relapsing types of multiple sclerosis, additional treatment options for progressive types of multiple sclerosis are needed, especially since the available treatments tend to focus on patients who are actively relapsing. In this context, the ASCEND trial by Raju Kapoor and colleagues1 was a two-part study that assessed whether natalizumab slows disease progression unrelated to relapse in patients with secondary progressive multiple sclerosis.
Source: Lancet Neurology - Category: Neurology Authors: Tags: Comment Source Type: research